4basebio

(4BB)
Sector: Pharmaceuticals & Biotechnology
1,316.67p
16.67p 1.28
Last updated: 11:00:10

Director dealings

Trade date Director Volume / Price Trade value Trade type
15/11/2024 Heikki Lanckriet 46,500 @ 1,325.00p £616,125.00 Buy
15/11/2024 Heikki Lanckriet 46,500 @ 1,325.00p £616,125.00 Sell
12/07/2022 Heikki Lanckriet 29,000 @ 415.00p £120,350.00 Transfer To
16/06/2022 David John Roth 5,000 @ 430.00p £21,500.00 Buy
12/05/2022 David John Roth 3,000 @ 480.00p £14,400.00 Buy
12/05/2022 Heikki Lanckriet 3,000 @ 470.00p £14,100.00 Buy
09/05/2022 Heikki Lanckriet 500 @ 500.00p £2,500.00 Buy
20/12/2021 Heikki Lanckriet 1,000 @ 650.00p £6,500.00 Buy
17/12/2021 Heikki Lanckriet 1,500 @ 650.00p £9,750.00 Buy
13/12/2021 Heikki Lanckriet 3,000 @ 652.00p £19,560.00 Buy
01/07/2021 Heikki Lanckriet 3,450 @ 467.00p £16,111.50 Buy

Director shareholdings

Name Holding Percent
Heikki Lanckriet 1,103,288 7.00%
Hansjörg Plaggemars 6,667 0.00%
Maria Del Pilar de la Huerta 6,667 0.00%
Timothy Paul McCarthy 2,388 0.00%
David John Roth 0 0.00%
Joseph Manuel Fernández 0 0.00%

Major shareholders

Institution name Holding Percent
DELPHI Unternehmensberatung AG 5,071,073 32.76%
Wilhelm K. T. Zours 5,071,073 32.76%
Elevage Medical Technologies Holdings 4,627,741 29.90%
M&G Plc 4,627,741 29.90%
Deutsche Balaton AG 4,432,637 28.64%
2invest AG 2,229,083 14.40%
Sparta AG 1,351,718 8.73%
Latonba AG 757,259 4.89%
Franciscus De Busschere 537,255 3.47%